On October 27, 2020 Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, reported that its Chief Executive Officer, Michael K. Handley, will host a conference call on Wednesday, October 28, 2020, at 8:00 a.m. ET, to discuss the proposed merger with Cleveland BioLabs (CBLI) and provide a strategic vision for the combined company (Press release, Cytocom, OCT 27, 2020, https://www.cytocom.com/2020/10/27/cytocom-strategic-vision-conference-call-reminder/?utm_source=rss&utm_medium=rss&utm_campaign=cytocom-strategic-vision-conference-call-reminder [SID1234569114]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information:

Interested participants and investors may access the conference call by dialing:

(646) 558-8656 (U.S.)
Conference ID: 841 7828 2704
Passcode: 281020
The conference call can also be accessed at https://cleartrustonline.com/cytocom. Approximately two hours following the live event, a webcast replay of the conference call will be available on Cytocom’s website https://www.cytocom.com/investors/ for approximately 30 days.